<html>

<head>
   <meta http-equiv="Content-Language" content="en-us">
   <meta name="GENERATOR" content="Microsoft FrontPage 5.0">
   <meta name="ProgId" content="FrontPage.Editor.Document">
   <meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
   <title>Diabetic Retinopathy</title>
   <style>
      p.MsoNormal {
         mso-style-parent: "";
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText {
         margin-bottom: .0001pt;
         line-height: 150%;
         font-size: 14.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.MsoBodyText2 {
         margin-bottom: .0001pt;
         text-align: justify;
         line-height: 150%;
         layout-grid-mode: char;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }

      p.Index {
         margin-bottom: .0001pt;
         font-size: 12.0pt;
         font-family: "Times New Roman";
         margin-left: 0in;
         margin-right: 0in;
         margin-top: 0in
      }
   </style>
</head>

<body>

   <p class="MsoNormal" align="center"><b><u>
            <span style="font-family: Arial">
               <font size="4">Diabetic Retinopathy</font>
            </span></u></b></p>
   <p class="MsoNormal" align="center" style="text-align: center"><b><u>
            <span style="font-family: Arial">
               <font size="4">Topic Highlights</font>
            </span></u></b></p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Diabetic retinopathy is a vascular disorder of the retina that results from
            diabetes.
         </font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b><br></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">Damage caused to the microvasculature and the vasoproliferative response may lead to bleeding in
            the retina and edema and abnormal growth of blood vessels.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">Diabetic retinopathy remains a leading cause for blindness, although the condition can be
            treated effectively.</font>
      </span>
   </p><br>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial"></span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;
         </font>
      </span><span style="font-family: Arial">
         <font size="4">This presentation describes the epidemiology and progression of diabetic retinopathy from
            nonproliferative to proliferative stage, their symptoms, diagnosis and treatment procedures ' available and
            upcoming.</font>
      </span>
   </p><br>
   <p class="MsoNormal" align="center" style="line-height: 150%">
      <b><u><span style="line-height: 150%; font-family: Arial">
               <font size="4">
                  Transcript</font>
            </span></u></b>
   </p><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/ Diabetes_mellitus"
               style="color: blue; text-decoration: underline; text-underline: single"> Diabetes mellitus</a> is a
            disorder characterized by <a href="https://en.m.wikipedia.org/wiki/hyperglycemia"
               style="color: blue; text-decoration: underline; text-underline: single"> hyperglycemia</a>, caused by
            defects in the secretion and/or in the action of <a href="https://en.m.wikipedia.org/wiki/insulin"
               style="color: blue; text-decoration: underline; text-underline: single">insulin</a>. Though diabetes can
            be controlled, long-term complications of the disease - <a href="https://en.m.wikipedia.org/wiki/nephropathy"
               style="color: blue; text-decoration: underline; text-underline: single">nephropathy</a>, <a
               href="https://en.m.wikipedia.org/wiki/retinopathy"
               style="color: blue; text-decoration: underline; text-underline: single">retinopathy</a>, <a
               href="https://en.m.wikipedia.org/wiki/neuropathy"
               style="color: blue; text-decoration: underline; text-underline: single">neuropathy</a> and <a
               href="https://en.m.wikipedia.org/wiki/atherosclerosis"
               style="color: blue; text-decoration: underline; text-underline: single">atherosclerosis</a> are common.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4"><a href="https://en.m.wikipedia.org/wiki/Eye disorders"
               style="color: blue; text-decoration: underline; text-underline: single">Eye disorders</a> are common in
            diabetics and can range from mild to severe in nature. Diabetic retinopathy, <a
               href="https://en.m.wikipedia.org/wiki/cataract"
               style="color: blue; text-decoration: underline; text-underline: single">cataract</a> and <a
               href="https://en.m.wikipedia.org/wiki/glaucoma"
               style="color: blue; text-decoration: underline; text-underline: single">glaucoma</a> may be caused by
            diabetes, with diabetic retinopathy potentially the most severe. Diabetic retinopathy constitutes a set of
            retinal abnormalities caused by damage to the microvasculature of the retina and to compensatory
            vasoproliferative responses to this damage in diabetes, and is a leading cause of blindness. The retinal
            changes in diabetic retinopathy include bleeding from fragile retinal blood vessels, <a
               href="https://en.m.wikipedia.org/wiki/edema"
               style="color: blue; text-decoration: underline; text-underline: single">edema</a>, and abnormal growth of
            blood vessels over the retina.</font>
      </span>
   </p><br>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp;In most developed countries, diabetic retinopathy is the primary cause for blindness
            among adults.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Diabetic retinopathy may be relatively asymptomatic until advanced stages of the
            disease.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Diabetic retinopathy can be effectively treated. Retinal laser photocoagulation is
            the principle approach used to curb disease advancement.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Regular comprehensive eye care allows early diagnosis and preventative management.
         </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">A frequent cause of new cases of blindness among adults in the age group of 20-64 years,
            diabetic retinopathy is chiefly pre-disposed by the duration of diabetes. Both type 1 and type 2 diabetic
            persons with a long history of diabetes are at risk of developing this vision threatening disease. The
            majority of persons with type 1 and approximately two thirds of those with type 2 diabetes may show evidence
            of retinopathy after the second decade of the disease. Apart from the duration of diabetes, poor diabetes
            and <a href="https://en.m.wikipedia.org/wiki/hypertension"
               style="color: blue; text-decoration: underline; text-underline: single">hypertension</a> control can
            contribute to the onset and progression of the diabetic retinopathy. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Diabetic retinopathy progresses from Nonproliferative (NPDR) in varying degrees from mild,
            moderate and severe to Proliferative (PDR). The asymptomatic nature of disease onset causes many diabetic
            patients to unwittingly progress rapidly towards severe vision loss. Early diagnosis, regular eye
            examinations, and appropriate intervention are key factors in the avoidance of visual impairment and
            blindness.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Diabetic retinopathy occurs as a result of changes in the microvasculature of the retina. Some
            of the changes include <a href="https://en.m.wikipedia.org/wiki/pericyte"
               style="color: blue; text-decoration: underline; text-underline: single">pericyte</a> death and thickening
            of the basement membranes of the blood vessels that result in changes in the blood-retinal barrier and make
            the blood vessels more permeable.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Nonproliferative (NPDR) is the initial stage of the disease. Early NPDR commences with the
            formation of small balloon-like swellings called micro-<a href="https://en.m.wikipedia.org/wiki/aneurysms"
               style="color: blue; text-decoration: underline; text-underline: single">aneurysms</a> that appear in the
            retina's small blood vessels. At this time, direct <a href="https://en.m.wikipedia.org/wiki/ophthalmoscopy"
               style="color: blue; text-decoration: underline; text-underline: single">ophthalmoscopy</a> reveals small
            red dots or blot <a href="https://en.m.wikipedia.org/wiki/hemorrhages"
               style="color: blue; text-decoration: underline; text-underline: single">hemorrhages</a>, which typically
            do not produce symptoms unless there is bleeding into the <a href="https://en.m.wikipedia.org/wiki/macula"
               style="color: blue; text-decoration: underline; text-underline: single">macula</a>. Visual loss in this
            condition is more typically caused by macular edema, due to the leakage of fluids from the damaged blood
            vessels that causes the macula to become swollen. This may lead to vision changes such as blurring.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Advanced NPDR occurs with the progression of disease. The significant finding at this stage is
            the appearance of cotton-wool spots. Cotton wool spots are discrete white spots with feathery edges that
            appear on the <a href="https://en.m.wikipedia.org/wiki/fundus"
               style="color: blue; text-decoration: underline; text-underline: single">fundus</a>. They arise due to <a
               href="https://en.m.wikipedia.org/wiki/capillary"
               style="color: blue; text-decoration: underline; text-underline: single">capillary</a> blockage that
            results in <a href="https://en.m.wikipedia.org/wiki/ischemia"
               style="color: blue; text-decoration: underline; text-underline: single">ischemia</a> or <a
               href="https://en.m.wikipedia.org/wiki/infarction"
               style="color: blue; text-decoration: underline; text-underline: single">infarction</a> of the nerve
            fibers covering the retina. NPDR presenting with irregular dilatations on the blood vessels or venous
            beadings, dilated tortuous intra-retinal vessels and extensive hemorrhages on the retina, may progress
            rapidly to Proliferative Retinopathy.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Proliferative (PDR) is most likely to result in complete loss of vision. This condition is
            caused by formation of new blood vessels in response to capillary blockage that prevents insufficient supply
            of blood to the retina. Neovasculazisation does not independently cause symptoms or vision loss. But the
            fragile nature of the blood vessels causes vitreous hemorrhage, bleeding into the <a
               href="https://en.m.wikipedia.org/wiki/vitreous_cavity"
               style="color: blue; text-decoration: underline; text-underline: single">vitreous cavity</a>. New blood
            vessels may also grow into the angle of the eye's anterior chamber causing <a
               href="https://en.m.wikipedia.org/wiki/Neovascular_Glaucoma"
               style="color: blue; text-decoration: underline; text-underline: single">Neovascular Glaucoma</a>. The
            fibrous proliferation accompanying neovascularization is associated with production of contractile proteins
            by <a href="https://en.m.wikipedia.org/wiki/fibrocytes"
               style="color: blue; text-decoration: underline; text-underline: single">fibrocytes</a> that can cause
            shrinkage, tearing or detachment of the retina. Retinal detachment or distortion are additional reasons for
            vision loss in PDR. The ophthalmoscopic changes seen in PDR are neovascularization with or without vitreous
            hemorrhage and fibrous proliferation, cotton-wool spots, extensive hemorrhages, venous abnormalities such as
            venous beading, loops and dilation. <a href="https://en.m.wikipedia.org/wiki/Macula_edema"
               style="color: blue; text-decoration: underline; text-underline: single">Macula edema</a> may also be
            present.</font>
      </span>
   </p><br><br>

   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Duration of diabetes: is the strongest predictor of diabetic retinopathy. All
            diabetic persons are at some risk of developing retinopathy. Those who have had diabetes for a longer period
            of time are at a greater risk. </font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Diabetic women in pregnancy: Women with pre-existing diabetes are at a risk of
            development or exacerbation of retinopathy during pregnancy.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Poor <a href="https://en.m.wikipedia.org/wiki/Glycemic "
               style="color: blue; text-decoration: underline; text-underline: single">Glycemic </a> control: Optimal
            glycemic control may considerably reduce the risk of developing diabetic retinopathy.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Poor hypertension control: Optimal blood pressure control substantially reduces the
            risk of retinopathy development.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Early stages of the disease are largely asymptomatic. However ocular symptoms that commonly
            present are:</font>
      </span>
   </p><br>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Transient refraction disturbances, usually <a
               href="https://en.m.wikipedia.org/wiki/myopic"
               style="color: blue; text-decoration: underline; text-underline: single">myopic</a> in nature.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Gradual vision loss, due to <a href="https://en.m.wikipedia.org/wiki/maculopathy"
               style="color: blue; text-decoration: underline; text-underline: single">
               maculopathy</a>.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Initial symptoms in PDR may include floating specs or spots.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Infrequently, ocular pain and <a href="https://en.m.wikipedia.org/wiki/erythema"
               style="color: blue; text-decoration: underline; text-underline: single">erythema</a> may be seen with
            secondary glaucoma that may occur as <a href="https://en.m.wikipedia.org/wiki/sequelae"
               style="color: blue; text-decoration: underline; text-underline: single">sequelae</a> to diabetic
            &nbsp;retinopathy.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Early detection of diabetic retinopathy is indispensable to the prevention of visual impairment.
            The various methods that are employed for diagnosis are</font>
      </span>
   </p><br>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/Visual_acuity_test"
               style="color: blue; text-decoration: underline; text-underline: single">Visual acuity test</a>: The most
            simple and widely used method. An illuminated Snellen chart is used to test each eye separately. A pinhole
            can correct refractive errors. Maculopathy is indicated when impaired visual acuity does not improve with
            the use of a pinhole. However, the simplicity of the test can be the reason for decreased sensitivity when
            performed by inexperienced or non-eye care providers.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Retinal examination: Direct opthalmoscopy with <a
               href="https://en.m.wikipedia.org/wiki/mydriasis"
               style="color: blue; text-decoration: underline; text-underline: single">mydriasis</a> (pupil dilatation).
         </font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Non-mydriatic retinal photography: Photographs of the optic disc and the retina
            generally improve the detection rate of &nbsp;maculopathy. The recent changes on the retina can be captured
            and the digital data can be preserved.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/Fluorescein_angiography"
               style="color: blue; text-decoration: underline; text-underline: single">Fluorescein angiography</a>:
            Fluorescein, a dye that is injected into the bloodstream, is used to detect the bleeding pattern in the
            retinal arteries. Bleeding blood vessels can be identified for initiating appropriate treatment.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/Optical_coherence_tomography"
               style="color: blue; text-decoration: underline; text-underline: single">Ocular Coherence Tomography
               (OCT)</a>: This method of scanning is used to measure the thickness of the retina.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/Tonometry"
               style="color: blue; text-decoration: underline; text-underline: single">Tonometry</a>: This is a test to
            determine intraocular pressure to detect glaucoma.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The high frequency of early onset retinopathy after diagnosis of diabetes and its tendency to
            rapidly progress to maculopathy underlines the necessity for regular and frequent comprehensive eye
            check-ups.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Frequent eye examinations are critical both for detection and for monitoring disease
            progression. Glycemic control and blood pressure control reduce the risk of developing diabetic retinopathy.
            In its initial stages, treatment may not be required, but in more advanced cases; treatment to curb further
            damage to the retina is of great importance.</font>
      </span>
   </p><br>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Laser photocoagulation: In a widely used technique in treating diabetic
            retinopathy, laser light is employed to seal &nbsp;bleeding retinal vessels, as well as providing an
            approach to reduction of the extent of the ischemic retina. &nbsp;Neovascularization may be restrained by
            focal retinal laser treatment. The resulting laser scars help to reduce &nbsp;neovascularization and may be
            employed in binding a dislodged retina to the posterior portion of the eye. This &nbsp;technique is utilized
            to diminish progress in visual impairment.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Scatter laser treatment: Multiple laser burns are made away from the centre of the
            retina. This technique, which is &nbsp;referred to as panretinal photocoagulation, causes vessel shrinkage.
            It may result in loss of peripheral vision and of &nbsp;color and night vision.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Intraocular <a href="https://en.m.wikipedia.org/wiki/steroid"
               style="color: blue; text-decoration: underline; text-underline: single">steroid</a> injection: A
            treatment for macular edema, this therapy reduces the amount of fluid leaking into the &nbsp;retina and
            improves vision. However the steroid injections may need to be administered repeatedly as diabetic
            &nbsp;retinopathy is chronic in nature, and this approach is associated with elevation of increased
            intraocular pressure. &nbsp;Intraocular steroid injection therapy in conjunction with laser surgery has
            maximal lasting effects.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/Cryotherapy"
               style="color: blue; text-decoration: underline; text-underline: single">
               Cryotherapy</a>: Cryotherapy or freezing is used when laser surgery fails due to the clouding of the
            usually clear vitreous &nbsp;fluid with blood. Cryotherapy causes shrinking of abnormal blood vessels and
            binds the retina to the posterior portion &nbsp;of the eye.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/Vitrectomy"
               style="color: blue; text-decoration: underline; text-underline: single">Vitrectomy</a>: Advanced stages
            of PDR are treated by vitrectomy. This microsurgery replaces the blood-filled vitreous &nbsp;with a clear
            solution.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; Retinal repair: Scar tissue may detach retina from the back of the eye. Severe loss
            of vision or even blindness can &nbsp;result if surgery for retinal repair is not performed.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; PKC <a href="https://en.m.wikipedia.org/wiki/Protein_kinase_C"
               style="color: blue; text-decoration: underline; text-underline: single">(Protein kinase-C)</a>
            inhibitors: PKC inhibitors such as <a href="https://en.m.wikipedia.org/wiki/Ruboxistaurin"
               style="color: blue; text-decoration: underline; text-underline: single">Ruboxistaurin</a> have shown
            results in animal models in reducing microvascular complications such as neovascularization and vessel
            bleeding.</font>
      </span>
   </p>
   <p class="MsoNormal" align="left"><b><span style="font-family: Arial">
            <font size="4">&nbsp;</font>
         </span></b></p>
   <p class="MsoNormal" style="text-indent: -.25in; margin-left: .5in" align="left">
      <font size="4"><span style="font-family: Arial">
         </span></font>&#9679;<span
         style="font-style: normal; font-variant: normal; font-weight: normal; font-family: Arial">
         <font size="4">&nbsp;&nbsp; <a href="https://en.m.wikipedia.org/wiki/Vascular_endothelial_growth_factor"
               style="color: blue; text-decoration: underline; text-underline: single">Vascular Endothelial Growth
               Factor</a> (VEGF) antagonists: Preliminary analysis suggests two agents acting to reduce &nbsp;VEGF
            activity; <a href="https://en.m.wikipedia.org/wiki/Pegaptanib"
               style="color: blue; text-decoration: underline; text-underline: single">Pegaptanib</a> and <a
               href="https://en.m.wikipedia.org/wiki/Ranibizumab"
               style="color: blue; text-decoration: underline; text-underline: single">Ranibizumab</a> have effects in
            reducing macular edema. Ongoing clinical trials are &nbsp;evaluating the use of these agents.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Comprehensive, regular ophthalmic examination should be performed for every person with diabetes
            on an annual basis beginning at the time of diagnosis of <a
               href="https://en.m.wikipedia.org/wiki/type_2_diabetes"
               style="color: blue; text-decoration: underline; text-underline: single">type 2 diabetes</a>, and after
            3-5 years of <a href="https://en.m.wikipedia.org/wiki/type_1_diabetes"
               style="color: blue; text-decoration: underline; text-underline: single">type 1 diabetes</a>. Optimal
            glycemic control can delay disease progression. Optimal blood pressure control can also delay disease
            progression.</font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">The frequency of eye examinations should be increased when retinopathy is suspected. Diabetic
            women in pregnancy are vulnerable to developing diabetic retinopathy. An initial eye examination is
            recommended during the first trimester, with regular follow-up throughout the pregnancy. Counseling on the
            risk of developing diabetic retinopathy coupled with the eye examination, enhances patient preparedness and
            the follow-up rate throughout the pregnancy. This guideline is relevant to women with pre-existing diabetes
            and not to those who develop <a href="https://en.m.wikipedia.org/wiki/gestational_diabetes"
               style="color: blue; text-decoration: underline; text-underline: single">gestational diabetes</a>. </font>
      </span>
   </p><br><br>
   <p class="MsoNormal" style="line-height: 150%" align="left">
      <span style="line-height: 150%; font-family: Arial">
         <font size="4">Patients who have macular edema and NPDR should not delay management and treatment. Early
            management and treatment may greatly reduce the likelihood of developing vision loss or resorting to
            vitrectomy. Visual rehabilitation should be encouraged in patients who have partial or complete vision loss.
         </font>
      </span>
   </p><br><br>

   <center>
      <div id="google_translate_element"></div>
   </center>
   

   


<script src="https://kit.fontawesome.com/a7d3f41661.js" crossorigin="anonymous"></script>
</body>

</html>